|
||||||||||||||||||||||||||
| SEC Info℠ | | | Home | | | Search | | | My Interests | | | Help | | | Sign In | | | Please Sign In | |||||||
|
||||||||||||||||||||||||||
As Of Filer Filing For·On·As Docs:Size Issuer Filing Agent 3/01/21 Akers Biosciences, Inc. 10-K 12/31/20 69:7.8M M2 Compliance LLC/FA |
Document/Exhibit Description Pages Size
1: 10-K Annual Report HTML 1.04M
2: EX-4.1 Instrument Defining the Rights of Security Holders HTML 71K
3: EX-21.1 Subsidiaries List HTML 20K
4: EX-23.1 Consent of Expert or Counsel HTML 19K
5: EX-31.1 Certification -- §302 - SOA'02 HTML 26K
6: EX-31.2 Certification -- §302 - SOA'02 HTML 26K
7: EX-32.1 Certification -- §906 - SOA'02 HTML 21K
8: EX-32.2 Certification -- §906 - SOA'02 HTML 21K
15: R1 Document and Entity Information HTML 54K
16: R2 Consolidated Balance Sheets HTML 111K
17: R3 Consolidated Balance Sheets (Parenthetical) HTML 60K
18: R4 Consolidated Statements of Comprehensive Loss HTML 106K
19: R5 Consolidated Statement of Changes in Shareholders' HTML 106K
Equity
20: R6 Consolidated Statement of Changes in Shareholders' HTML 33K
Equity (Parenthetical)
21: R7 Consolidated Statements of Cash Flows HTML 132K
22: R8 Organization and Description of Business HTML 24K
23: R9 Significant Accounting Policies HTML 101K
24: R10 Recent Developments, Liquidity and Management's HTML 71K
Plans
25: R11 Inventories HTML 22K
26: R12 Trade and Other Payables HTML 26K
27: R13 Discontinued Operations HTML 84K
28: R14 Share-based Compensation HTML 74K
29: R15 Equity HTML 60K
30: R16 Income Taxes HTML 40K
31: R17 Commitments and Contingencies HTML 40K
32: R18 Related Parties HTML 26K
33: R19 Employee Benefit Plan HTML 26K
34: R20 Subsequent Events HTML 22K
35: R21 Significant Accounting Policies (Policies) HTML 166K
36: R22 Significant Accounting Policies (Tables) HTML 43K
37: R23 Recent Developments, Liquidity and Management's HTML 24K
Plans (Tables)
38: R24 Trade and Other Payables (Tables) HTML 25K
39: R25 Discontinued Operations (Tables) HTML 86K
40: R26 Share-based Compensation (Tables) HTML 73K
41: R27 Income Taxes (Tables) HTML 39K
42: R28 Significant Accounting Policies (Details HTML 94K
Narrative)
43: R29 Significant Accounting Policies - Schedule of HTML 25K
Marketable Securities (Details)
44: R30 Significant Accounting Policies - Schedule of HTML 37K
Estimated Useful Life of Property Plant and
Equipment (Details)
45: R31 Significant Accounting Policies - Schedule of HTML 24K
Estimated Useful Life of Other Intangible Assets
(Details)
46: R32 Significant Accounting Policies - Schedule of HTML 26K
Other Information Related to Leases (Details)
47: R33 Significant Accounting Policies - Schedule of HTML 33K
Anti-dilutive Securities Excluded from Computation
of Earnings Per Share (Details)
48: R34 Recent Developments, Liquidity and Management's HTML 290K
Plans (Details Narrative)
49: R35 Recent Developments, Liquidity and Management's HTML 30K
Plans - Summary of Milestone Events Payment
(Details)
50: R36 Recent Developments, Liquidity and Management's HTML 41K
Plans - Summary of Milestone Events Payment
(Details) (Parenthetical)
51: R37 Inventories (Details Narrative) HTML 22K
52: R38 Trade and Other Payables - Schedule of Trade and HTML 31K
Other Payables (Details)
53: R39 Discontinued Operations - Schedule of Discontinued HTML 262K
Operations (Details)
54: R40 Share-based Compensation (Details Narrative) HTML 88K
55: R41 Share-based Compensation - Summary of Stock HTML 81K
Options Activity (Details)
56: R42 Share-based Compensation - Summary of Restricted HTML 53K
Stock Units Activity (Details)
57: R43 Share-based Compensation - Summary of Warrant HTML 94K
Activity (Details)
58: R44 Equity (Details Narrative) HTML 209K
59: R45 Income Taxes (Details Narrative) HTML 43K
60: R46 Income Taxes - Schedule of Income Tax (Benefit)/ HTML 33K
Provision (Details)
61: R47 Income Taxes - Schedule of Reconciliation of HTML 35K
Income Taxes using Statutory U.S. Income Tax Rate
and Benefit from Income Taxes (Details)
62: R48 Income Taxes - Schedule of Deferred Tax Assets and HTML 31K
Related Valuation Allowances (Details)
63: R49 Commitments and Contingencies (Details Narrative) HTML 63K
64: R50 Related Parties (Details Narrative) HTML 37K
65: R51 Employee Benefit Plan (Details Narrative) HTML 28K
66: R52 Subsequent Events (Details Narrative) HTML 32K
68: XML IDEA XML File -- Filing Summary XML 117K
67: EXCEL IDEA Workbook of Financial Reports XLSX 123K
9: EX-101.INS XBRL Instance -- aker-20201231 XML 1.80M
11: EX-101.CAL XBRL Calculations -- aker-20201231_cal XML 168K
12: EX-101.DEF XBRL Definitions -- aker-20201231_def XML 896K
13: EX-101.LAB XBRL Labels -- aker-20201231_lab XML 1.64M
14: EX-101.PRE XBRL Presentations -- aker-20201231_pre XML 1.04M
10: EX-101.SCH XBRL Schema -- aker-20201231 XSD 303K
69: ZIP XBRL Zipped Folder -- 0001493152-21-005129-xbrl Zip 209K
Exhibit 23.1
CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM
We hereby consent to the incorporation by reference in the Registration Statements on Form S-1 (File No. 333-234447 and 333-235359) and Form S-3 (File No. 333-217390, 333-234449, 333-238631 and 333-248095) of Akers Biosciences, Inc. of our report dated March 1, 2021 relating to the consolidated financial statements, which appears in this Form 10-K.
/s/ Morison Cogen LLP
Blue Bell, Pennsylvania
C:
| This ‘10-K’ Filing | Date | Other Filings | ||
|---|---|---|---|---|
 | ||||
| Filed on: | 3/1/21 | None on these Dates | ||
| For Period end: | 12/31/20 | |||
| List all Filings | ||||
As Of Filer Filing For·On·As Docs:Size Issuer Filing Agent 2/23/23 MyMD Pharmaceuticals, Inc. 424B5 1:459K M2 Compliance LLC/FA 8/17/22 MyMD Pharmaceuticals, Inc. 424B5 1:406K M2 Compliance LLC/FA 8/16/21 MyMD Pharmaceuticals, Inc. 10-Q 6/30/21 66:7.6M M2 Compliance LLC/FA 5/11/21 MyMD Pharmaceuticals, Inc. 424B3 1:392K M2 Compliance LLC/FA 4/28/21 MyMD Pharmaceuticals, Inc. S-3/A 5:840K M2 Compliance LLC/FA 3/25/21 MyMD Pharmaceuticals, Inc. S-3 5:793K M2 Compliance LLC/FA |